CA2863653A1 - Pluripotent germ layer origin antigen presenting cancer vaccine - Google Patents

Pluripotent germ layer origin antigen presenting cancer vaccine Download PDF

Info

Publication number
CA2863653A1
CA2863653A1 CA2863653A CA2863653A CA2863653A1 CA 2863653 A1 CA2863653 A1 CA 2863653A1 CA 2863653 A CA2863653 A CA 2863653A CA 2863653 A CA2863653 A CA 2863653A CA 2863653 A1 CA2863653 A1 CA 2863653A1
Authority
CA
Canada
Prior art keywords
cells
cancer
gamma
ifn
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2863653A
Other languages
English (en)
French (fr)
Inventor
Andrew CORNFORTH
Robert DILLMAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lisata Therapeutics Inc
Original Assignee
California Stem Cells Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by California Stem Cells Inc filed Critical California Stem Cells Inc
Publication of CA2863653A1 publication Critical patent/CA2863653A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4245—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
CA2863653A 2012-02-02 2013-01-31 Pluripotent germ layer origin antigen presenting cancer vaccine Abandoned CA2863653A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261594304P 2012-02-02 2012-02-02
US61/594,304 2012-02-02
PCT/US2013/024123 WO2013116505A1 (en) 2012-02-02 2013-01-31 Pluripotent germ layer origin antigen presenting cancer vaccine

Publications (1)

Publication Number Publication Date
CA2863653A1 true CA2863653A1 (en) 2013-08-08

Family

ID=48905824

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2863653A Abandoned CA2863653A1 (en) 2012-02-02 2013-01-31 Pluripotent germ layer origin antigen presenting cancer vaccine

Country Status (13)

Country Link
US (1) US20150064217A1 (https=)
EP (1) EP2809775B1 (https=)
JP (1) JP2015506698A (https=)
KR (1) KR20140143361A (https=)
CN (1) CN104540937A (https=)
AU (1) AU2013215116A1 (https=)
CA (1) CA2863653A1 (https=)
GB (1) GB2512558A (https=)
HK (2) HK1209455A1 (https=)
IL (1) IL233928A0 (https=)
NZ (1) NZ628292A (https=)
SG (1) SG11201404543UA (https=)
WO (2) WO2013116505A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103599528B (zh) * 2013-12-04 2015-08-05 深圳市合一康生物科技股份有限公司 人树突状细胞疫苗的制备方法
EP3925968A3 (en) 2014-10-07 2022-03-02 Cytlimic Inc. Hsp70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell
US11291718B2 (en) 2016-10-11 2022-04-05 Cytlimic Inc. Method for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein
CN110198717A (zh) * 2017-01-11 2019-09-03 国立研究开发法人国立癌症研究中心 免疫治疗药
EP3582793A4 (en) * 2017-02-17 2020-12-16 Aivita Biomedical, Inc. METHODS TO IMPROVE TUMOR IMMUNOGENICITY AND COMPOSITIONS FOR AUTOLOGOUS ANTI-CANCER IMMUNOTHERAPEUTICS USING MODIFIED TUMOR CELLS AND MODIFIED DENDRITIC CELLS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL140796A0 (en) * 2001-01-08 2002-02-10 Hadasit Med Res Service An autologous anti-cancer vaccine
CA2459713C (en) * 2001-09-06 2015-08-18 Northwest Biotherapeutics, Inc. Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response
JP5623004B2 (ja) * 2004-10-25 2014-11-12 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 熱ショックをかけたメラノーマ細胞体が装填された樹状細胞
WO2007016340A2 (en) * 2005-07-29 2007-02-08 Providence Health System Defective ribosomal products in blebs (dribbles) and methods of use to stimulate an immune response
CA2700436C (en) * 2006-09-28 2017-04-18 John S. Yu Cancer vaccines and vaccination methods
US20090041792A1 (en) * 2007-07-19 2009-02-12 Istituto Superiore Di Sanita Dendritic cells, uses therefor, and vaccines and methods comprising the same

Also Published As

Publication number Publication date
GB201414403D0 (en) 2014-10-01
CN104540937A (zh) 2015-04-22
SG11201404543UA (en) 2014-08-28
JP2015506698A (ja) 2015-03-05
AU2013215116A1 (en) 2014-08-21
US20150064217A1 (en) 2015-03-05
HK1209455A1 (en) 2016-04-01
HK1202432A1 (en) 2015-10-02
EP2809775B1 (en) 2018-06-13
KR20140143361A (ko) 2014-12-16
EP2809775A1 (en) 2014-12-10
IL233928A0 (en) 2014-09-30
NZ628292A (en) 2016-09-30
EP2809775A4 (en) 2015-07-01
WO2013116541A1 (en) 2013-08-08
WO2013116505A1 (en) 2013-08-08
GB2512558A (en) 2014-10-01

Similar Documents

Publication Publication Date Title
US9555058B2 (en) Antigen presenting cancer vaccine
Palucka et al. Recent developments in cancer vaccines
WO2016081554A1 (en) Immunogenic compositions prepared from tumor cells derived from peripheral blood and originating from a solid tumor and their use
AU2023208190B2 (en) Methods relating to activated dendritic cell compositions and immunotherapeutic treatments for subjects with advanced cancers
EP2809775B1 (en) Pluripotent germ layer origin antigen presenting cancer vaccine
Nguyen-Pham et al. Immunotherapy using dendritic cells against multiple myeloma: how to improve?
Bot et al. Cancer vaccines
HK1230080A1 (en) Antigen presenting cancer vaccine with gamma interferon
NZ623917B2 (en) Antigen presenting cancer vaccine
HK1258885B (en) Methods relating to activated dendritic cell compositions for subjects with advanced cancers

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180116

FZDE Discontinued

Effective date: 20200131